Principal Investigator
Jaime Martinez Martinez
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20221185
Clinical Trial Summary
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy
Phase
Phase III
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Yasniel Espinosa Gonzalez
Phone Number
+1 (239) 6593962
Email
yxe82@miami.edu